{"id":1301,"date":"2016-03-22T11:18:00","date_gmt":"2016-03-22T11:18:00","guid":{"rendered":"https:\/\/pepharm.gr\/ema-communication-launch-of-prime\/"},"modified":"2016-03-22T11:18:00","modified_gmt":"2016-03-22T11:18:00","slug":"ema-communication-launch-of-prime","status":"publish","type":"post","link":"https:\/\/pepharm.gr\/en\/ema-communication-launch-of-prime\/","title":{"rendered":"EMA Communication: Launch of PRIME"},"content":{"rendered":"<div dir=\"ltr\" style=\"text-align: left;\">\n<div style=\"text-align: justify;\">The European Medicines Agency would like  to inform you that the new PRIME (PRIority MEdicines) scheme to  strengthen support to medicines that target an unmet medical need has  been launched today. The scheme focuses on medicines that may offer a  major therapeutic advantage over existing treatments, or benefit  patients with no treatment options. Through PRIME, the Agency offers  early, proactive and enhanced support to medicine developers to optimise  the generation of robust data on a medicine\u2019s benefits and risks and  enable accelerated assessment of marketing applications.<\/div>\n<div style=\"text-align: justify;\"><\/div>\n<div style=\"text-align: justify;\">A <a href=\"http:\/\/goo.gl\/2yBIiT\" target=\"_blank\" rel=\"noopener\">press release<\/a> on PRIME and further information have been published on the EMA  website, including details on how to apply. In the event of queries, a  dedicated e-mail has been set up (  <a href=\"mailto:prime@ema.europa.eu\">prime@ema.europa.eu<\/a>).<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The European Medicines Agency would like to inform you that the new PRIME (PRIority MEdicines) scheme to strengthen support to medicines that target an unmet medical need has been launched today. The scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients with no treatment options. Through PRIME, [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pmpro_default_level":"","footnotes":""},"categories":[54],"tags":[],"class_list":["post-1301","post","type-post","status-publish","format-standard","hentry","category-54","pmpro-has-access"],"acf":[],"_links":{"self":[{"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/posts\/1301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/comments?post=1301"}],"version-history":[{"count":0,"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/posts\/1301\/revisions"}],"wp:attachment":[{"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/media?parent=1301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/categories?post=1301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pepharm.gr\/en\/wp-json\/wp\/v2\/tags?post=1301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}